Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Triple-Negative Breast Carcinoma: early-phase trial registry
8 of 21 indexed Triple-Negative Breast Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #797 of 28,707 conditions by registered trial count.
21 US clinical trials · 8 currently recruiting · #797 of 28,707 conditions by registered trial count
Triple-Negative Breast Carcinoma: 21 US clinical trials tracked, 8 recruiting.
Triple-Negative Breast Carcinoma is the subject of 21 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 8 of these trials.
Enrollment posture brief
Registry condition triple-negative-breast-carcinoma
OPEN 8 | RECR 38% | LATE 2 | EARLY 15 | RANK #797 | SPON 8
Volume-matched condition peers
Nearest open-share peer: Behavior, Health (38% recruiting · 21 trials)
Triple-Negative Breast Carcinoma lists 8 open slots (38% of 21 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Triple-Negative Breast Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Triple-Negative Breast Carcinoma recruits in line with its size-band peers.
8 of 21 indexed trials (38.1%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Triple-Negative Breast Carcinoma research.
National Cancer Institute (NCI) accounts for 8 of 21 trials (38.1%). 11 distinct sponsors appear on at least one study for this condition label.
-
Most Triple-Negative Breast Carcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 67 among the 21 trials that report a genuine target (sentinel values excluded). 14 of those (66.7%) plan for fewer than 100 participants.
-
Triple-Negative Breast Carcinoma research is mostly interventional.
21 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
21 total, page 1 of 1
Access to Genetic Testing in Underserved Patients With Cancer
University of Southern California
NCT06422455
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
Laura Huppert, MD, BA
NCT03971409
Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
Mayo Clinic
NCT06635980
Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer
Northwestern University
NCT03213041
Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer
Thomas Jefferson University
NCT04959474
Food for Thought - A Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast Cancer
Ohio State University Comprehensive Cancer Center
NCT06582615
Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
Vandana Abramson
NCT07016399
Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer
Ohio State University Comprehensive Cancer Center
NCT05677802
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
National Cancer Institute (NCI)
NCT02954874
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
NRG Oncology
NCT02488967
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
National Cancer Institute (NCI)
NCT01116648
DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer
M.D. Anderson Cancer Center
NCT02744053
Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy
M.D. Anderson Cancer Center
NCT02411656
Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer
National Cancer Institute (NCI)
NCT02883062
Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer
National Cancer Institute (NCI)
NCT01251874
Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer
National Cancer Institute (NCI)
NCT04052555
Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer
National Cancer Institute (NCI)
NCT01349959
Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer
National Cancer Institute (NCI)
NCT01624441
Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer
M.D. Anderson Cancer Center
NCT02530489
Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer
Vanderbilt-Ingram Cancer Center
NCT02672475
Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer
National Cancer Institute (NCI)
NCT01575522
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 9 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Triple-Negative Breast Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Triple-Negative Breast Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Triple-Negative Breast Carcinoma page
21 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 8 Triple-Negative Breast Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Triple-Negative Breast Carcinoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Triple-Negative Breast Carcinoma condition card totals 21 registered trials; most-linked intervention Laboratory Biomarker Analysis; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.